| Drug | X3 vs X2 (%) | X3 (€) | Hypothesis |
|---|---|---|---|
| Infliximab | +19% | €1 34 902 | 1st assumption |
| +3% | €21 952 | 2nd assumption | |
| -49% | €3 42 533 | 3rd assumption | |
| Etanercept | -16% | €2 19 429 | 1st assumption |
| -18% | €2 48 623 | 2nd assumption | |
| -38% | €5 19 064 | 3rd assumption | |
| Rituximab | +8% | €1 01 208 | 1st assumption |
| -24% | €2 83 583 | 2nd assumption | |
| -42% | €4 96 875 | 3rd assumption | |